Dopamine supersensitivity psychosis (DSP) is observed in patients with schizophrenia under antipsychotic treatment, and it is characterized by rebound psychosis, an uncontrollable psychotic episode following a stable state and tardive dyskinesia. DSP, first described in patients taking typical antipsychotics in the late 1970s, sometimes appears even in patients who are treated with current atypical antipsychotics. It was recently demonstrated that DSP can have a negative impact on the long-term prognosis of schizophrenia patients and that DSP could be involved in the etiology of some cases of treatment-resistant schizophrenia. Accumulating evidence suggests that an up-regulation of dopamine D2 receptors (DRD2) in the brain caused by long-term exposure to antipsychotics is related to the DSP phenomenon. The present review describes the clinical characteristics and the etiology of DSP in the era of second-generation antipsychotics for patients with schizophrenia. Based on the mechanism of DSP, several potential treatments for patients presenting with a DSP episode or the dopamine supersensitivity state are also discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0269881117728428 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early-life risperidone alters locomotor responses to apomorphine and quinpirole in adulthood.
Behav Brain Res
September 2024
Department of Statistics, College of Arts and Sciences, University of Kentucky, Lexington, KY 40504, United States; Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40504, United States.
An escalating trend of antipsychotic drug use in children with ADHD, disruptive behavior disorder, or mood disorders has raised concerns about the impact of these drugs on brain development. Since antipsychotics chiefly target dopamine receptors, it is important to assay the function of these receptors after early-life antipsychotic administration. Using rats as a model, we examined the effects of early-life risperidone, the most prescribed antipsychotic drug in children, on locomotor responses to the dopamine D/D receptor agonist, apomorphine, and the D/D receptor agonist, quinpirole.
View Article and Find Full Text PDFDifferential Activation States of Direct Pathway Striatal Output Neurons during l-DOPA-Induced Dyskinesia Development.
J Neurosci
June 2024
Department of Neurology, Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35294
l-DOPA-induced dyskinesia (LID) is a debilitating motor side effect arising from chronic dopamine (DA) replacement therapy with l-DOPA for the treatment of Parkinson's disease. LID is associated with supersensitivity of striatal dopaminergic signaling and fluctuations in synaptic DA following each l-DOPA dose, shrinking the therapeutic window. The heterogeneous composition of the striatum, including subpopulations of medium spiny output neurons (MSNs), interneurons, and supporting cells, complicates the identification of cell(s) underlying LID.
View Article and Find Full Text PDFWithdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022.
Psychopharmacology (Berl)
June 2024
Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine and Toulouse University Hospital (CHU), 37 Allées Jules-Guesde 31000, Toulouse, France.
Article Synopsis
- Withdrawal syndrome (WDS) may occur after stopping antipsychotic medications, potentially due to increased dopamine activity, especially with drugs closely binding to D2 receptors.* ! -
- Analysis of pharmacovigilance data revealed that insomnia, anxiety, and depression were common withdrawal symptoms, with tiotixene showing the highest risk of WDS among antipsychotics studied.* ! -
- The study found a weak correlation between the binding affinity of D2/5HT2A receptors and WDS risk, indicating that not all antipsychotics carry the same withdrawal risk, with some like chlorpromazine being safer.* !
Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis.
Psychopharmacology (Berl)
February 2024
Pharmacy Department, Maudsley Hospital, London, SE5 8AZ, UK.
Rationale: Dopamine antagonists induce dopamine receptor supersensitivity. This may manifest in late-appearing movement disorders (tardive dyskinesia (TD). VMAT-2 inhibitors reduce dopaminergic transmission but have limited activity at postsynaptic receptors and so may have antipsychotic activity with lower risk of tardive dyskinesia.
View Article and Find Full Text PDFWorsening stimulant use disorder outcomes coinciding with off-label antipsychotic prescribing: a commonly unrecognised side effect?
BMJ Case Rep
October 2023
BC Centre on Substance Use, The University of British Columbia, Vancouver, British Columbia, Canada
Antipsychotic medications exert their effects via dopamine antagonism and are widely used off-label among persons with substance use disorders (SUD). While dopamine antagonists are recognised to stimulate food craving and weight gain, outside of possibly increasing nicotine craving and use, their impact on other SUD outcomes is poorly recognised. In this context, research has demonstrated that antipsychotic therapy can produce 'supersensitivity' to dopamine, enhancing the motivational effects of addictive drugs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!